Dr. Pakkala on Clinical Trial Enrollment for Patients With Breast Cancer and Brain Metastases

Video

In Partnership With:

Suchita Pakkala, MD, discusses the importance for clinical trial enrollment for patients with breast cancer who have brain metastases.

Suchita Pakkala, MD, assistant professor, Department of Hematology and Medical Oncology site medical director, Infusion Services, Emory University School of Medicine, Emory University Hospital Midtown, discusses the importance for clinical trial enrollment for patients with breast cancer who have brain metastases.

Additional efforts are ongoing to enroll patients with metastatic breast cancer who have brain metastases to clinical trials to better evaluate if drugs are active against central nervous system (CNS) metastases, Pakkala says. Patients with breast cancer and CNS metastases typically have a smaller window for treatment, making it vital to quickly find clinical trials where they could be eligible, Pakkala explains.

Keeping trials open at many institutions can benefit patients with brain metastases and provide additional insights into the effectiveness of different treatments, Pakkala concludes.

Related Videos
Jorge J. Castillo, MD,
Heinz-Josef Lenz, MD, FACP
Sundar Jagannath, MBBS, director, Center of Excellence for Multiple Myeloma, professor of medicine (hematology and medical oncology), The Tisch Cancer Institute, Mount Sinai
Omid Hamid, MD, professor, medicine, Cedars-Sinai; director, Clinical Research and Immunotherapy, director, Cutaneous Oncology and Melanoma, The Angeles Clinic and Research Institute
Christina L. Roland, MD, MS, FACS
Ashish Saxena, MD, PhD
Shruti Tiwari, MD
Scott Kopetz, MD, PhD, FACP
Katharina Hoebel, MD, PhD
Catherine C. Coombs, MD, associate clinical professor, medicine, University of California, Irvine School of Medicine